This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
psoriatic-arthritis
Psoriatic Arthritis
Seronegative inflammatory arthritis in ~30% of psoriasis patients; 5 clinical patterns; CASPAR criteria. Driven by IL-17A, IL-23, TNF-α, and IL-36 axes targeting skin, entheses, and joints. Approved biologics: anti-TNF, anti-IL-17A, anti-IL-23, anti-IL-12/23, JAK/TYK2 inhibitors.
Entry Metadata
| Field | Value |
|---|---|
| ID | psoriatic-arthritis |
| Name | Psoriatic Arthritis |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970. · PubMed 28273019
- Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329-1339. · PubMed 26422723
- Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1). Lancet. 2020;395(10230):1115-1125. · PubMed 32178765
- Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. · PubMed 16871531